Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on developing novel therapies and vaccines. Its work spans central nervous system (CNS) disorders, immunology, and infectious diseases. The company's pipeline includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), which received FDA approval as the first new treatment for fibromyalgia in over 15 years.
Beyond TONMYA, Tonix is advancing candidates such as TNX-102 SL for acute stress disorder, TNX-4800 for Lyme disease prevention, and TNX-1500 for organ transplant rejection. The company also markets acute migraine products Zembrace Symtouch and Tosymra. Its technical domains include biotechnology, drug development, and vaccine development.
Tonix describes its culture as grounded in scientific rigor, integrity, and purpose-driven research. The company emphasises a patient-first philosophy, stating that it listens to patients' lived experiences and aims to develop treatments that make individuals feel seen, heard, and empowered. Employees are described as energised by the possibility of meaningful impact in healthcare.
